Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Infectious Disease · Dengue

Can I get a Dengue vaccine if I've never had Dengue?

At a Glance

Yes, you can get the Qdenga vaccine if you have never had Dengue fever, as it is safe for those without prior infection. However, the older Dengvaxia vaccine is strictly for people who have already had Dengue and is dangerous for first-timers. Consult a doctor before traveling.

If you have never had Dengue fever, your ability to get vaccinated depends heavily on where you live or are traveling. The most important thing to know is that your history of Dengue infection completely changes which vaccines are safe for you.

Currently, there are two main vaccines for Dengue fever, but they have very different rules about who can receive them:

Qdenga (TAK-003): Safe for First-Time Protection

Qdenga is a newer vaccine that is approved in many countries for people whether they have had Dengue before or not [1][2][3]. Research shows that it is safe and effective for individuals who are “Dengue-naive” (meaning they have never been infected) [2][3].

Because of this, Qdenga does not require you to take a blood test before getting vaccinated [3][4]. It has become an important option for travelers visiting places where Dengue is common [1].

Availability and Travel Planning:
It is important to know that while Qdenga is available in the European Union, the UK, and various Dengue-endemic countries, it is not currently approved in the United States [5].
Additionally, for those who can access it, Qdenga requires planning ahead. It is given as a two-dose series, spaced three months apart, so travelers need to start the process well before their trip [2][6].

Dengvaxia (CYD-TDV): Only for Past Infections

Dengvaxia is an older vaccine that is strictly for people who have already had Dengue fever at least once [7][3].

If you have never had Dengue, getting the Dengvaxia vaccine can actually be dangerous [7]. The vaccine can act like a “silent” first infection for your body [8]. If you are bitten by a Dengue-infected mosquito later on, your immune system may overreact in a way that makes the illness much worse—a phenomenon known as antibody-dependent enhancement (when antibodies from a previous infection or vaccine help the virus infect cells, leading to more severe disease) [7][8].

Because of this risk, the World Health Organization recommends, and regulatory agencies require, that anyone getting Dengvaxia must first pass a blood test confirming a past infection [3][4][9]. (Note: The manufacturer recently announced it is discontinuing the production of Dengvaxia, though some doses may remain available temporarily).

Who Cannot Get Either Vaccine?

Both Qdenga and Dengvaxia are live-attenuated vaccines, meaning they contain a weakened version of the virus [10][11]. Because they use a live virus, there are specific groups who generally cannot safely receive either vaccine, regardless of their past Dengue history:

  • Pregnant women: Live vaccines are typically not recommended during pregnancy due to potential risks [10][11][12].
  • People with weakened immune systems: Individuals who are severely immunocompromised (such as those undergoing certain cancer treatments or taking strong immunosuppressive medications) usually cannot receive live vaccines [11][13][12].
  • Breastfeeding mothers: Data is limited, so caution is advised, and you should consult a doctor before getting a live vaccine while breastfeeding [12].

Vaccines Are Not a Replacement for Bug Spray

Even if you are able to get vaccinated, no Dengue vaccine provides 100% protection against the disease. It is crucial to continue using strict mosquito protection methods when traveling to an area with Dengue. This includes using EPA-registered insect repellent, wearing long sleeves and pants, and sleeping under a mosquito net if your accommodations are not air-conditioned or screened.

Next Steps for Travelers

If you are planning to travel to an area where Dengue is common, speak with a travel medicine specialist or your primary care doctor. They can help determine if a vaccine is available in your country, approved for your specific age (as age approvals vary by country), and appropriate for your health timeline.

Common questions in this guide

Can I get the Qdenga vaccine if I have never had Dengue?
Yes, the Qdenga vaccine is safe and approved for individuals who have never been infected with Dengue. It does not require a blood test beforehand, making it an excellent option for travelers visiting areas where Dengue is common.
Is the Dengvaxia vaccine safe for first-time Dengue protection?
No, Dengvaxia is strictly for people who have previously had Dengue fever. If you receive it without a prior infection, it can act as a silent first infection and potentially make future Dengue illnesses much more severe.
Is the Qdenga Dengue vaccine available in the United States?
Currently, the Qdenga vaccine is not approved for use in the United States. However, it is available in the European Union, the UK, and several countries where Dengue is common.
Who cannot safely receive a Dengue vaccine?
Because Dengue vaccines contain live-attenuated viruses, they are generally unsafe for pregnant women, breastfeeding mothers, and people with severely weakened immune systems. Always consult your doctor to ensure a live vaccine is safe for your health profile.
Do I still need to use bug spray if I am vaccinated against Dengue?
Yes, no Dengue vaccine provides complete protection against the disease. You must continue using strict mosquito prevention methods, such as applying EPA-registered insect repellent and wearing long sleeves, when traveling to high-risk areas.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the Qdenga vaccine approved and available in our country, and am I within the approved age range?
  2. 2.My trip is coming up in less than three months; is there any benefit to getting the first dose of Qdenga before I leave?
  3. 3.Since I am traveling to a high-risk area and might not be fully vaccinated, what specific mosquito repellents and prevention methods do you recommend?
  4. 4.Are there any medications or health conditions I have that would make a live-attenuated vaccine unsafe for me?
  5. 5.What symptoms should I watch out for during and after my trip that would indicate I might have caught Dengue?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    TAK-003: development of a tetravalent dengue vaccine.

    Sáez-Llorens X, DeAntonio R, Low JGH, et al.

    Expert review of vaccines 2025; (24(1)):324-338 doi:10.1080/14760584.2025.2490295.

    PMID: 40207772
  2. 2

    Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.

    Tricou V, Yu D, Reynales H, et al.

    The Lancet. Global health 2024; (12(2)):e257-e270 doi:10.1016/S2214-109X(23)00522-3.

    PMID: 38245116
  3. 3

    Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review.

    Naderian R, Eslami M, Ahmad S, et al.

    Reviews in medical virology 2025; (35(3)):e70035 doi:10.1002/rmv.70035.

    PMID: 40195054
  4. 4

    Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

    Durbin AP

    Current opinion in virology 2020; (43()):79-87 doi:10.1016/j.coviro.2020.09.005.

    PMID: 33164790
  5. 5

    Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.

    LeFevre I, Bravo L, Folschweiller N, et al.

    NPJ vaccines 2023; (8(1)):75 doi:10.1038/s41541-023-00670-6.

    PMID: 37230978
  6. 6

    Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

    Sáez-Llorens X, Tricou V, Yu D, et al.

    The Lancet. Infectious diseases 2018; (18(2)):162-170 doi:10.1016/S1473-3099(17)30632-1.

    PMID: 29122463
  7. 7

    Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study.

    Ylade M, Crisostomo MV, Daag JV, et al.

    The Lancet. Infectious diseases 2024; (24(7)):737-745 doi:10.1016/S1473-3099(24)00099-9.

    PMID: 38527474
  8. 8

    Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua.

    Narvaez F, Montenegro C, Juarez JG, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.02.11.24302393.

    PMID: 38405964
  9. 9

    Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.

    Wilder-Smith A, Hombach J, Ferguson N, et al.

    The Lancet. Infectious diseases 2019; (19(1)):e31-e38 doi:10.1016/S1473-3099(18)30494-8.

    PMID: 30195995
  10. 10

    Advances in the Epidemiology, Pathogenesis, Diagnostic Methods, and Vaccine Development of Dengue Fever: A Comprehensive Review.

    Dong B, Feng S, Feng X

    Viral immunology 2025; (38(2)):53-60 doi:10.1089/vim.2024.0087.

    PMID: 39995247
  11. 11

    Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection.

    Wang R, Kim B, Mishra H, Kain KC

    Pediatric investigation 2025; (9(3)):304-310 doi:10.1002/ped4.70005.

    PMID: 40969293
  12. 12

    Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

    Gilbert PB, Huang Y, Juraska M, et al.

    The American journal of tropical medicine and hygiene 2019; (101(1)):164-179 doi:10.4269/ajtmh.18-0534.

    PMID: 31115304
  13. 13

    Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.

    Tan BEK, Tham SK, Poh CL

    Vaccines 2025; (13(5)) doi:10.3390/vaccines13050532.

    PMID: 40432141

This page provides educational information about Dengue vaccines and travel preparation. Always consult a travel medicine specialist or your healthcare provider to determine if a vaccine is safe and appropriate for your specific health needs.

Get notified when new evidence is published on Dengue fever.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.